Hourglass Capital LLC Buys 3,330 Shares of Novo Nordisk A/S (NYSE:NVO)

Hourglass Capital LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 21.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 18,950 shares of the company’s stock after purchasing an additional 3,330 shares during the quarter. Hourglass Capital LLC’s holdings in Novo Nordisk A/S were worth $1,630,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at approximately $28,000. Center for Financial Planning Inc. grew its holdings in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $42,000. Carolina Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the third quarter valued at $48,000. Finally, Dunhill Financial LLC lifted its position in Novo Nordisk A/S by 196.8% in the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after purchasing an additional 311 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $77.94 on Friday. Novo Nordisk A/S has a 1-year low of $77.82 and a 1-year high of $148.15. The company has a 50 day moving average of $88.65 and a 200-day moving average of $109.83. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. The firm has a market cap of $349.75 billion, a price-to-earnings ratio of 23.69, a PEG ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is 21.88%.

Wall Street Analysts Forecast Growth

NVO has been the topic of several analyst reports. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Wednesday. They set an “equal weight” rating for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.